OBJECTIVES: To determine the clinicopathologic variables and survival in the patients with synchronous endometrial and ovarian cancer (synchronous group) compared to the patients with primary endometrial cancer with ovarian metastasis (metastatic group). METHODS: The medical records of 423 endometrial cancer patients who received primary surgery were reviewed. Fourteen patients were diagnosed as synchronous group while 49 patients were diagnosed as metastatic group. RESULTS: The median age in synchronous group was significantly younger than metastatic group (47 versus 56 years). More nulliparous and premenopausal patients were demonstrated in synchronous group. Synchronous group had significantly higher incidence of low grade tumor and lower incidence of deep myometrial invasion. All patients in synchronous group presented in stage I endometrial cancer. Moreover, most patients (85.7%) presented in early stage ovarian cancer and only 14.3% in advanced stage ovarian cancer. Synchronous group had better disease free survival (DFS) and overall survival (OS) than metastatic group. Estimated 5 years DFS was 64.2% versus 41.5%, (P = 0.17) and 5 years OS was 92.8% versus 48.5% (P = 0.036). CONCLUSION: The patients in synchronous group were younger, more nulliparous and had a better prognosis than the patients in the metastatic group.
OBJECTIVES: To determine the clinicopathologic variables and survival in the patients with synchronous endometrial and ovarian cancer (synchronous group) compared to the patients with primary endometrial cancer with ovarian metastasis (metastatic group). METHODS: The medical records of 423 endometrial cancerpatients who received primary surgery were reviewed. Fourteen patients were diagnosed as synchronous group while 49 patients were diagnosed as metastatic group. RESULTS: The median age in synchronous group was significantly younger than metastatic group (47 versus 56 years). More nulliparous and premenopausal patients were demonstrated in synchronous group. Synchronous group had significantly higher incidence of low grade tumor and lower incidence of deep myometrial invasion. All patients in synchronous group presented in stage I endometrial cancer. Moreover, most patients (85.7%) presented in early stage ovarian cancer and only 14.3% in advanced stage ovarian cancer. Synchronous group had better disease free survival (DFS) and overall survival (OS) than metastatic group. Estimated 5 years DFS was 64.2% versus 41.5%, (P = 0.17) and 5 years OS was 92.8% versus 48.5% (P = 0.036). CONCLUSION: The patients in synchronous group were younger, more nulliparous and had a better prognosis than the patients in the metastatic group.